{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:22Z","timestamp":1790790202676,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2013\/624"],"award-info":[{"award-number":["CAN 2013\/624"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALF Governmental Funds","award":["ALFGBG-146611"],"award-info":[{"award-number":["ALFGBG-146611"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12985-018-0994-7","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T04:23:45Z","timestamp":1526358225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles"],"prefix":"10.1186","volume":"15","author":[{"given":"Kasthuri","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf E.","family":"Rydell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Norkrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hel\u00e9ne","family":"Norder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7462","authenticated-orcid":false,"given":"Magnus","family":"Lindh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"994_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, HLA J, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"994_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"C-J Chen","year":"2006","unstructured":"Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"994_CR3","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1111\/liv.12345","volume":"34","author":"SB Larsson","year":"2014","unstructured":"Larsson SB, Eilard A, Malmstr\u00f6m S, Hannoun C, Dhillon AP, Norkrans G, et al. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int. 2014;34:e238\u201345.","journal-title":"Liver Int"},{"key":"994_CR4","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJV Thompson","year":"2010","unstructured":"Thompson AJV, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933\u201344.","journal-title":"Hepatology"},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398\u2013411.","journal-title":"J Hepatol"},{"key":"994_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep.27381","volume":"61","author":"F van B\u00f6mmel","year":"2015","unstructured":"van B\u00f6mmel F, Bartens A, Mysickova A, Hofmann J, Kr\u00fcger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66\u201376.","journal-title":"Hepatology"},{"key":"994_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiv397","volume":"213","author":"L Jansen","year":"2015","unstructured":"Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus Pregenomic RNA is present in Virions in plasma and is associated with a response to Pegylated interferon alfa-2a and Nucleos(t)ide analogues. J Infect Dis. 2015;213:224\u201332.","journal-title":"J Infect Dis"},{"key":"994_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1749-6632.2001.tb03886.x","volume":"945","author":"R Breitkreutz","year":"2001","unstructured":"Breitkreutz R, Zhang W, Lee M, Hoffmann A, Tokus M, Su Q, et al. Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci. 2001;945:195\u2013206.","journal-title":"Ann N Y Acad Sci"},{"key":"994_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00535-006-1856-4","volume":"41","author":"A Rokuhara","year":"2006","unstructured":"Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol Springer-Verlag. 2006;41:785\u201390.","journal-title":"J Gastroenterol Springer-Verlag"},{"key":"994_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1365-2893.2000.00236.x","volume":"7","author":"M Lindh","year":"2000","unstructured":"Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat. 2000;7:258\u201367.","journal-title":"J Viral Hepat"},{"key":"994_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036349","volume":"7","author":"S Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m S, Larsson SB, Hannoun C, Lindh M. Hepatitis B Viral DNA Decline at Loss of HBeAg Is Mainly Explained by Reduced cccDNA Load \u2013 Down-Regulated Transcription of PgRNA Has Limited Impact. Ryu W-S, editor. PLoS ONE. 2012;7:e36349.","journal-title":"PLoS ONE"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/viro.2001.1352","volume":"295","author":"A Laras","year":"2002","unstructured":"Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of Precore mRNA synthesis is associated with mutations in the hepatitis B virus Core promoter. Virology. 2002;295:86\u201396.","journal-title":"Virology"},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jvh.12387","volume":"22","author":"N D\u00e9sir\u00e9","year":"2015","unstructured":"D\u00e9sir\u00e9 N, Ngo Y, Franetich JF, Dembele L, Mazier D, Vaillant JC, et al. Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. J Viral Hepat. 2015;22:718\u201326.","journal-title":"J Viral Hepat"},{"key":"994_CR14","doi-asserted-by":"crossref","unstructured":"Rydell GE, Prakash K, Norder H, Lindh M. Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. Virology. 2017;509:67\u201370","DOI":"10.1016\/j.virol.2017.05.017"},{"key":"994_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65:700\u201310.","journal-title":"J Hepatol"},{"key":"994_CR16","doi-asserted-by":"crossref","unstructured":"Beck J. Hepatitis B virus replication. WJG 2007;13:48.","DOI":"10.3748\/wjg.v13.i1.48"},{"key":"994_CR17","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1093\/nar\/24.17.3295","volume":"24","author":"AH Kidd","year":"1996","unstructured":"Kidd AH, Kidd-Ljunggren K. A revised secondary structure model for the 3\u2019-end of hepatitis B virus pregenomic RNA. Nucleic Acids Res. 1996;24:3295\u2013301.","journal-title":"Nucleic Acids Res"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-0994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-018-0994-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-0994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:12:32Z","timestamp":1557861152000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-0994-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-0994-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"13 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies were conducted in accordance with the Declaration of Helsinki and approved by the Regional Ethical Review Board in Gothenburg, Sweden. An informed consent was obtained from each patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"86"}}